Idenix Pharmaceuticals Inc. NasdaqGS: IDIX

This is one high beta stock. The swings are notorious here, and you would likely not buy at current levels if you were ONLY looking at the chart:

Quoting Ron Renaud, the President and CEO for Idenix, from the August 7th release:

“In the second quarter, we saw significant progress of our lead HCV development program, samatasvir, and continue to be on track to report data from the first patient cohort in the fourth quarter of this year,” said Ron Renaud, Idenix’s President and Chief Executive Officer. “We remain committed to our HCV nucleotide franchise, and we are actively pursuing additional paths forward with the ultimate goal remaining the evaluation of an all-oral internally developed pan-genotypic combination regimen including samatasvir and a nucleotide inhibitor.”

In reading bullet points from that same release, we see that there have been no “treatment-related” serious adverse events in the clinical data to date. I hope there none serious at all.

They gave some upcoming info:

 

 

SEE IDIX IN STOCKGURU’S 12 BIOTECH BREAKOUT STOCKS

SEE THE ENTIRE LIST OF STOCKGURU’S 12 BIOTECH BREAKOUT STOCKS